The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Beyond technology, regulations weigh heavily on the minds of pharma executives. Four out of 10 leaders believe regulatory ...

While expressing a desire for revenue growth is common, understanding the “why” behind that intention is crucial. Delving ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical ...

Lilly announced several changes to its executive leadership team. 1 These changes are mostly related to the company’s ...

The use of RWD data in place of placebo groups is improving various elements across the clinical trial space.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing ...

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and ...

In an effort to combat the state’s shortage of primary care physicians, Blue Cross Blue Shield of Massachusetts is offering ...

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health ...

Commissioner Markary announced the plans alongside the results of a generative AI pilot for scientific reviewers.

Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following ...